by Eric Christianson | Sep 20, 2023 | Endocrine Medication and Disease State Clinical Pearls
A few months back, I compared one of the newest SGLT2 inhibitors in bexagliflozin to the other agents in this class of medication. To sum up my analysis, bexagliflozin provided nothing significantly different from the other SGLT2 inhibitors. In fact, it has less...
by Eric Christianson | Aug 30, 2023 | Uncategorized
In this polypharmacy case study, we review a medication list and try to identify areas to reduce medications and avoid adverse reactions. EK is a 66-year-old female with a past medical history of insomnia, diabetes, GERD, hypertension, hyperlipidemia, obesity,...
by Eric Christianson | Aug 16, 2023 | Polypharmacy Cases And The Prescribing Cascade
As a geriatric pharmacist, I’m always on high alert for the prescribing cascade. I outline my top 5 examples of the prescribing cascade in diabetes care in this article. Metformin and Loperamide Metformin has been the go-to first-line agent of choice for years....
by Eric Christianson | Aug 9, 2023 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls
There’s always this voice in the back of my head that always cautions me that all that glitters is not gold. After being heralded as the next savior in weight loss by the media, the GLP-1 Agonists/GIP agonists have come under more scrutiny lately in the news. A...
by Eric Christianson | Jun 7, 2023 | Clinical Pharmacy News and New Drug Updates
A new SGLT2i is now on the market, promoting a new option for diabetes management. Bexagliflozin (Brenzavvy) got FDA approval in January of this year adding it to the list of SGLT2 inhibitors. With a few already on the scene, it bears the question, is bexagliflozin...
